Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT


To demonstrate that the specificity of the Hummingbird microRNA profile for the diagnosis of lung cancer in a cohort of patients who meet current eligibility criteria for lung cancer screening in the U.S. is superior to the specificity of LDCT.

Study Start Date

November, 01 2017

Estimated Completion Date

October 2018


No interventions cited

Study ID

Hummingbird Diagnostics -- HMBDx USA-0001



Trial ID


Study Type


Trial Phase


Enrollment Quota



Hummingbird Diagnostics

Inclusion Criteria

    1. Subject is undergoing LDCT screening for lung cancer. 2. Subject is 55 to 80 years of age. 3. Subject has a minimum 30 pack-year smoking history. 4. Subject has not quit smoking more than 15 years ago. 5. Subject is without symptoms attributable to lung cancer. 6. Subject is able and willing to provide informed consent.

Exclusion Criteria

    1. Subject has a history of lung, gastrointestinal, hematological, breast, thyroid, or genitourinary cancers within the past ten years. 2. Subject is known to be infected with HIV, HBV, HCV, or tuberculosis or any other Biosafety Level 3 (BSL III) pathogen infections.




55 Years to 80 Years

Accepts Healthy Volunteers

Not Listed

Study Locations and Contact Information (3)

Study Location Distance Name Phone Email
Brigham and Womens Hospital - Boston, Massachusetts 2.6 miles Francine Jaconson MD 617-732-6285
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Amita Sharma MD 617-724-4254
Lahey Hospital Medical Center - Burlington, Massachusetts 11.0 miles Kimberly RiegerChrist PhD 781-744-2969 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.